Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH aberrations and IDH1 codon 105 SNP occur in about 30% of younger patients with AML, mostly with diploid karyotype.
|
22020636 |
2012 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
|
31145495 |
2019 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase 1 (IDH1) are found in 6% of AML patients.
|
31586149 |
2020 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NPM1, DNMT3A, and IDH2 mutations were more common while biallelic CEBPA and IDH1 mutations were less seen in e-AML patients. s-AML patients carried a higher frequency of KMT2A-AF9.
|
31348835 |
2019 |
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of primary leukemic blasts confirmed high levels of 2-HG in AMLs with IDH1/IDH2 mutations.
|
21647154 |
2011 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With median follow-up of 8.3 months for 174 adults with IDH1-mutated R/R AML treated with 500 mg ivosidenib daily, the CR + CRh rate was 33% [95% confidence interval (CI), 26-40], median duration of response was 8.2 (95% CI, 5.6-12) months, and conversion from TD to TI occurred in 37% of patients.
|
30692099 |
2019 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
|
23954893 |
2013 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high MEBE score, defined as high expression of at least two of the four genes, predicted a significantly shorter overall survival (OS) (HR 2.29, 95 % CI 1.3-4.09, P= .005) and time to AML progression (HR 4.83, 95 % CI 2.01-11.57, P< .001) compared to a low MEBE score in multivariate analysis independent of karyotype, percentage of bone marrow blasts, transfusion dependence, ASXL1, and IDH1 mutation status.
|
22488406 |
2012 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both patients with IDH1 mutations had AML-M0 subtype and MLL-partial tandem duplication.
|
23365461 |
2013 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.
|
29439493 |
2018 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, AML patients with IDH mutations display a significantly reduced number of other well characterized AML-associated mutations and/or associated chromosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.
|
20171147 |
2010 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This analysis defines the clinical outcome associated with IDH-mutations in both the front-line and salvage AML treatment settings, and confirms that response rate and OS for both IDH-mutated and IDH wild-type AML patients is comparable.
|
26016821 |
2015 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 SNP rs11554137 was recently reported in association with poor prognosis in normal karyotype adult acute myeloid leukemia (AML).
|
21873548 |
2011 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients.
|
26466372 |
2015 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
|
20376086 |
2010 |
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in the NADP(+)-dependent isocitrate dehydrogenase genes 1 and 2 (IDH1 and IDH2) have recently been found in adult acute myeloid leukemia (AML) patients with a prevalence rising up to 33%.
|
21647152 |
2011 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our study showed a high frequency of FLT3, RUNX1, and IDH mutations in AML-M0, suggesting that these mutations played a role in the pathogenesis and served as potential therapeutic targets in this rare and unfavorable subtype of AML.
|
25022553 |
2014 |
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively identified forty-two patients with AML treated with DNA methyltransferase inhibitors (DNMTIs) decitabine (n = 36) or azacitidine (n = 6) and performed analysis of stored samples for the presence of IDH1 and IDH2 mutations.
|
25651001 |
2015 |